Trial · NCT04680052
Results by group508
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 508
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First | FL: Tafasitamab + Rituximab + Lenalidomide | 22.37 | 95% Confidence Interval 19.22 to NA | months | |
FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First | FL: Placebo + Rituximab + Lenalidomide | 13.93 | 95% Confidence Interval 11.53 to 16.39 | months | |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Tafasitamab + Rituximab + Lenalidomide | 6 months | 92.4 | 95% Confidence Interval 88.3 to 95.1 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Placebo + Rituximab + Lenalidomide | 6 months | 78.2 | 95% Confidence Interval 72.7 to 82.7 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Tafasitamab + Rituximab + Lenalidomide | 12 months | 79.0 | 95% Confidence Interval 72.8 to 84.0 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Placebo + Rituximab + Lenalidomide | 12 months | 54.0 | 95% Confidence Interval 47.1 to 60.5 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Tafasitamab + Rituximab + Lenalidomide | 18 months | 61.9 | 95% Confidence Interval 53.4 to 69.3 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Placebo + Rituximab + Lenalidomide | 18 months | 38.5 | 95% Confidence Interval 30.8 to 46.1 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Tafasitamab + Rituximab + Lenalidomide | 2 years | 41.7 | 95% Confidence Interval 28.4 to 54.6 | percent probability |
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL: Placebo + Rituximab + Lenalidomide | 2 years | 31.8 | 95% Confidence Interval 23.6 to 40.2 | percent probability |
| Overall Population: PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Tafasitamab + Rituximab + Lenalidomide | 23.95 | 95% Confidence Interval 22.34 to NA | months | |
| Overall Population: PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Placebo + Rituximab + Lenalidomide | 16.39 | 95% Confidence Interval 13.86 to 18.66 | months | |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Tafasitamab + Rituximab + Lenalidomide | 6 months | 92.7 | 95% Confidence Interval 89.0 to 95.1 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Placebo + Rituximab + Lenalidomide | 6 months | 80.0 | 95% Confidence Interval 75.0 to 84.0 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Tafasitamab + Rituximab + Lenalidomide | 12 months | 79.7 | 95% Confidence Interval 74.1 to 84.2 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Placebo + Rituximab + Lenalidomide | 12 months | 58.7 | 95% Confidence Interval 52.4 to 64.4 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Tafasitamab + Rituximab + Lenalidomide | 18 months | 64.1 | 95% Confidence Interval 56.7 to 70.6 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Placebo + Rituximab + Lenalidomide | 18 months | 44.7 | 95% Confidence Interval 37.6 to 51.5 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Tafasitamab + Rituximab + Lenalidomide | 2 years | 48.0 | 95% Confidence Interval 36.1 to 59.0 | percent probability |
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First | FL and MZL: Placebo + Rituximab + Lenalidomide | 2 years | 33.1 | 95% Confidence Interval 24.1 to 42.3 | percent probability |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04680052/results